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Objectives The goal of this study was to compare the angiographic outcomes of everolimus-eluting stents (EES) and
sirolimus-eluting stents (SES) in a head-to-head manner.
Background EES have been shown to be superior to paclitaxel-eluting stents in inhibiting late loss (LL) and clinical outcome.
Whether EES may provide similar angiographic and clinical outcomes compared with SES is undetermined.
Methods This was a prospective, randomized, open-label, multicenter trial to demonstrate the noninferiority of EES com-
pared with SES in preventing LL at 9 months. A total of 1,443 patients undergoing percutaneous coronary inter-
vention were randomized 3:1 to receive EES or SES. Routine follow-up angiography was recommended at 9
months. The primary endpoint was in-segment LL at 9 months, and major secondary endpoints included in-stent
LL at 9 months, target lesion failure, cardiac death, nonfatal myocardial infarction, target lesion revasculariza-
tion, and stent thrombosis at 12 months. Data were managed by an independent management center, and clini-
cal events were adjudicated by an independent adjudication committee.
Results Clinical follow-up was available in 1,428 patients and angiographic follow-up in 924 patients (1,215 lesions).
The primary endpoint of the study (in-segment LL at 9 months) was 0.11  0.38 mm and 0.06  0.36 mm for
EES and SES, respectively (p for noninferiority  0.0382). The in-stent LL was also noninferior (EES 0.19  0.35
mm; SES 0.15  0.34 mm; p for noninferiority  0.0121). The incidence of clinical endpoints was not statisti-
cally different between the 2 groups, including target lesion failure (3.75% vs. 3.05%; p  0.53) and stent
thrombosis (0.37% vs. 0.83%; p  0.38).
Conclusions EES were noninferior to SES in inhibition of LL after stenting, which was corroborated by similar rates of clinical
outcomes. (Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting [EXCELLENT];
NCT00698607) (J Am Coll Cardiol 2011;58:1844–54) © 2011 by the American College of Cardiology Foundation
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October 25, 2011:1844–54 Everolimus- Versus Sirolimus-Eluting Stents in PCIDrug-eluting stents (DES) have revolutionized the field
of interventional cardiology. Newer stents are developed
with hopes of improving efficacy and/or safety. Everolimus-
eluting stents (EES) are second-generation DES using the
MULTI-LINK VISION stent platform (Abbott Vascular,
Santa Clara, California) combined with everolimus con-
tained in a polymer coating (1). In the SPIRIT II (Clinical
Evaluation of the Xience V Everolimus Eluting Coronary
Stent System in the Treatment of Patients With de novo
Native Coronary Artery Lesions) and SPIRIT III random-
ized trials, EES were noninferior and subsequently superior
to paclitaxel-eluting stents (PES) with regard to in-stent
late loss (LL) at 180 days (2,3). Moreover, the clinical
outcomes of EES were superior to PES in the recent
SPIRIT IV and COMPARE (Comparison of the everoli-
mus eluting Xience V stent with the paclitaxel eluting Taxus
Liberte stent in all-comers: a randomized open label trial)
trials, in which the primary clinical endpoints were reduced
by 38% and 31%, respectively (4,5).
See page 1855
However, EES have not been compared with sirolimus-
eluting stents (SES), which are the most efficacious of the
first-generation DES with the least amount of LL reported
(6–10). SES showed lower cardiovascular event rates com-
pared with both PES and zotarolimus-eluting stents in the
EST (Comparison of the Efficacy and Safety of
otarolimus-Eluting Stent with Sirolimus-Eluting and
acliTaxel-Eluting Stent for Coronary Lesions) and SORT-
UT III (Danish Organisation for Randomised Trials with
linical Outcome) randomized trials, respectively (11,12).
However, the stent and polymer platform is different between
EES and SES, and EES have the thinnest stent and polymer
thickness (88.6 m) of all the available DES in Korea.
Therefore, the present trial was designed to compare the
efficacy of EES versus SES in reducing LL in patients
undergoing percutaneous coronary intervention (PCI).
Methods
Study design and population. The prospective, open-label,
blinded endpoint adjudication, randomized, EXCELLENT
(Efficacy of Xience/Promus Versus Cypher to Reduce Late
Loss After Stenting) trial enrolled patients from 19
cardiac centers in Korea between June 2008 and July
2009. The study design has been published previously
(13). The study protocol was approved by the ethics
committee at each participating center and was con-
ducted according to the principles of the Declaration of
Helsinki. All patients provided written informed consent
for participation in the trial.
Patients were eligible if they had at least 1 lesion in the
native coronary vessel with a reference diameter of 2.25 to 4.25
mm, stenosis of more than 50% by visual estimation, and
evidence of myocardial ischemia (stable angina, unstable an- ogina, recent myocardial infarction
[MI], silent ischemia, positive func-
tional study, or reversible changes
on electrocardiogram consistent
with ischemia). Documentation of
ischemia was not mandatory for
lesions with75% stenosis. There
ere no limitations for inclusion in
he number of lesions, or involved
essels, or on the length of the
esions in efforts to reflect real-life
linical practice. Exclusion criteria
ere ST-segment elevation MI
ithin 72 h; severely compromised
entricular dysfunction (ejection
raction 25%) or cardiogenic
hock; significant left main disease
defined as stenosis of more than
0%); in-stent or in-segment re-
tenosis of a previously implanted
tent; chronic total occlusion; true
ifurcation lesions requiring a
lanned 2-stent strategy; allergy to
ntiplatelet drugs, heparin, stain-
ess steel, contrast agents, everolimus, or sirolimus; serum
reatinine 3.0 mg/dl or dependence on dialysis; life expec-
ancy1 year; or active participation in another clinical study.
andomization and procedures. Patients were random-
zed 3:1 to either receive EES (Xience V [Abbott Vascular,
anta Clara, California] and Promus [Boston Scientific,
atick, Massachusetts]) or SES (Cypher Select [Cordis
orporation, Bridgewater, New Jersey]). Randomization
as conducted using a Web-based online randomization
ystem after diagnostic angiography and before PCI. Ran-
omization was stratified according to enrolling sites, the
resence of diabetes, and long lesions.
Balloon angioplasty and stent implantation were per-
ormed according to standard techniques. It was recom-
ended that all significant lesions be fully covered by one or
ultiple stents using the same randomly assigned stent,
xcept when the allocated stent could not be inserted or was
ot suitable for the lesion, in which case crossover to another
evice at the discretion of the operator was permitted. Staged
CI (defined as procedures planned at the time of the index
rocedure) was allowed at the operators’ discretion as long as
he second PCI would be performed within 4 weeks of the
ndex procedure using the allocated stent.
Before the index procedure, all patients received at least 300
g of aspirin and a 300- to 600-mg loading dose of clopi-
ogrel. Unfractionated heparin was administered throughout
he procedure to maintain an activated clotting time of 250 s or
onger. Administration of glycoprotein IIb/IIIa inhibitors was
t the discretion of the operator. At discharge, all patients were
aintained with at least 75 mg/day of aspirin and 75 mg/day
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
LL  late loss
MI  myocardial infarction
MLD  minimal luminal
diameter
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
coronary angiography
RR  relative risk
SES  sirolimus-eluting
stent(s)
TLF  target lesion failure
TLR  target lesion
revascularizationf clopidogrel for at least 6 months.
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Everolimus- Versus Sirolimus-Eluting Stents in PCI October 25, 2011:1844–54Follow-up. For evaluation of the primary endpoint, all pa-
tients were recommended to undergo angiographic follow-up
at 9 months. Clinical follow-up was performed at 1, 3, 9, and
12 months after index PCI and will be continued annually for
up to 5 years. Patients were followed up by telephone contacts
or office visits. At follow-up, patients were specifically ques-
tioned regarding the occurrence of any adverse events or the
presence of anginal symptoms.
Quantitative coronary angiography. Quantitative analysis
of coronary angiographic images was performed at a central
core laboratory (Seoul National University Hospital Cardio-
vascular Clinical Research Center Angiographic Core Lab-
oratory) by specialized quantitative coronary angiography
(QCA) technicians unaware of the purpose of this study.
The Cardiovascular Angiography Analysis System 5.7
QCA system (Pie Medical Imaging, Maastricht, the Neth-
erlands) was used for automated contour detection and
quantification. All angiograms performed more than 30
days after index PCI showing restenosis or thrombosis
(diameter stenosis more than 50%) qualified as an endpoint
angiogram. If an angiogram was performed between 1 and
5 months and restenosis was not present in any study lesion,
the requirement for the 9-month angiogram was not con-
sidered to be met, and thus the 9-month angiographic
follow-up was again recommended. All scheduled and
unscheduled angiograms from 6 to 12 months were consid-
ered as 9-month follow-up angiograms.
Projections in which foreshortening of the analysis seg-
ment could be minimized and where the severity of the
stenosis could be maximized were used in analysis. Same
views with identical projections for baseline and first and
second angiographic follow-ups were used. Using the guid-
ing catheter for calibration, the minimal luminal diameter
(MLD) and reference vessel diameter were measured before
and after the index procedure and at first and second
angiographic follow-up. Diameter stenosis was defined as
the ratio of MLD and diameter of reference segment, and
angiographic binary restenosis was denoted as diameter
stenosis more than 50% within the target lesion. LL was the
difference in MLD between angiograms immediately after
the index procedure and follow-up angiogram. Acute gain
was defined as the increment of MLD immediately after the
index procedure. All measurements were performed for
both the stented segment (in-stent) and 5-mm proximal and
distal margins of the stented segment (in-segment).
Study endpoints. The primary endpoint for this study was
in-segment LL at 9 months. The major secondary angio-
graphic endpoint was in-stent LL at 9 months. Secondary
clinical endpoints included target lesion failure (TLF) (de-
fined as the composite of cardiac death, target vessel–related
MI, and clinically indicated target lesion revascularization
[TLR] at 12 months), target vessel failure (defined as the
composite of cardiac death, target vessel–related MI, and
clinically indicated target vessel revascularization at 12
months), individual components of TLF and target vessel
revascularization, all deaths, periprocedural and spontane- cous MI, and stent thrombosis (defined according to the
Academic Research Consortium criterion) (14). Other an-
giographic endpoints were angiographic pattern of resteno-
sis and in-stent and in-segment percentage diameter steno-
sis at 9 months. Data were managed by an independent
management center, and clinical events were adjudicated by
an independent adjudication committee.
Statistical analysis. On the basis of QCA results from the
SIRIUS (Sirolimus-Eluting Stent in De Novo Native Cor-
onary Lesions), E-SIRIUS, C-SIRIUS, SIRTAX (Ran-
domized Comparison of a Sirolimus- vs. a Paclitaxel-
Eluting Stent for Coronary Revascularization), and the
SPIRIT II and III trials (2,3,6,15-17), we assumed the LL
of EES to be 0.2 0.41 mm and SES to be 0.2 0.48 mm.
nrollment of 1,233 patients (924 in the EES arm and 309
n the SES arm) would provide the study with a statistical
ower of 90% to confirm noninferiority within 0.1 mm at a
-sided significance level of 0.05, allowing for 20% of
atients not undergoing follow-up angiography. Angio-
raphic analysis was performed on a per-patient (index
esion only, primary analysis) and a per-lesion (all lesions)
asis. The index lesion to be included in the primary
er-patient analysis was determined randomly by using a
omputer program before QCA analysis (Online Appen-
ix). For the per-lesion analysis, a generalized estimating
quations model using an exchangeable working correlation
atrix was used to assess the treatment effect by taking the
lustering effect within patient into account.
For baseline characteristics and clinical outcomes, cate-
orical variables were analyzed by using the chi-square or
isher exact tests, whereas continuous variables were as-
essed by using the Student t test. For subgroup analysis of
LF, the logistic regression model was used to assess the
nteraction between the treatment and each subgroup. The time
o each clinical endpoint was assessed using the Kaplan-
eier method, and the log-rank test was used to compare
he incidence of each endpoint between groups. All clinical
utcomes were analyzed on an intention-to-treat basis
hereas angiographic outcome was analyzed on a per-
rotocol basis (those that received allocated stents and
eceived follow-up angiography).
Analyses were performed using SPSS version 17.0 for
indows (SPSS Inc., Chicago, Illinois) and SAS version
.2 (SAS Institute Inc., Cary, North Carolina).
esults
aseline characteristics and procedural results. A total of
,443 patients (1,927 lesions) were enrolled in the study and
andomly assigned to receive EES (n  1,079; 1,459
esions) or SES (n  364; 468 lesions). Figure 1 shows the
rial profile and flow of the study patients. The baseline
atient characteristics are shown in Table 1, and the
aseline lesion and procedural characteristics are displayed
n Table 2. The baseline patient, lesion, and procedural
haracteristics were mostly similar and comparable between
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October 25, 2011:1844–54 Everolimus- Versus Sirolimus-Eluting Stents in PCIthe 2 groups except the frequency of patients with a history
of cerebrovascular accident, which was more common in the
SES group; the number of implanted stents per patient,
which was marginally higher in the EES group; and the
final balloon pressure, which was significantly higher in the
SES group (p  0.01). The proportion of patients present-
ing with acute coronary syndrome was 52%, those with
diabetes was 38.1%, and those with multivessel disease was
52.0%; the mean stented length was 28.05 mm/lesion and
37.54 mm/patient, reflecting the near real-world nature of
the patients enrolled in the study. One notable characteristic
of the present study was the high percentage of patients
receiving intravascular ultrasound–guided stenting (43.5%).
The device success rate was excellent (both more than 99%)
and did not differ significantly between groups.
Angiographic results. Quantitative angiographic results at
baseline, after the procedure, and at follow-up for the
per-protocol patients are shown in Table 3 (index lesion)
nd Online Table 1 (all lesions). There were no significant
ifferences in angiographic measurements of lesions before
nd after the procedure. Angiographic follow-up at 9
onths was performed in 66.7% of the total patients (n 
Figure 1 Trial Profile
A total of 1,443 patients were randomized 3:1 to receive everolimus-eluting stents
lyzed according to the intention-to-treat basis. BMS  bare-metal stents; CABG 
intervention; POBA  “plain old balloon angioplasty”; tx  treatment.24; 1,215 lesions), 67.4% (n  708; 948 lesions) in theES group, and 64.5% (n  216; 267 lesions) in the SES
roup. The primary endpoint of the study, mean in-segment
L, was 0.11  0.38 mm in the EES group and 0.06 
.36 mm in the SES group (difference in LL: 0.05 mm
1-sided 95% upper confidence interval (CI): 0.096], p for
oninferiority  0.0382). The upper CI was within the
re-specified noninferiority margin, and thus the results of
he in-segment LL met the criteria for noninferiority of
ES versus SES (noninferiority margin  0.1 mm). The
n-stent LL showed similar findings; the mean in-stent LL
as 0.19  0.35 mm and 0.15  0.34 mm for the EES and
ES groups, respectively (difference in LL: 0.04 [1-sided
5% upper CI: 0.083], p for noninferiority  0.0121). The
cumulative in-stent and in-segment MLD curves of the 2
groups at 3 time points (before, immediately after, and 9
months after PCI) are shown in Online Figure 1. The
angiographic results (noninferiority of EES) were similar in
the intention-to-treat population, including those who did
not receive the allocated stents (Online Table 2).
Clinical outcomes up to 1 year. The cumulative clinical
outcomes at 1 month and up to 1 year after PCI are shown
in Table 4. At 1 month, the incidence of clinical events was
) or sirolimus-eluting stents (SES). Clinical outcomes of the patients were ana-
ry artery bypass graft; DES  drug-eluting stents; PCI  percutaneous coronary(EES
coronasimilar between the 2 groups. Clinical follow-up at 1 year
se; EES
sirolimu
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Everolimus- Versus Sirolimus-Eluting Stents in PCI October 25, 2011:1844–54was completed for 1,428 patients (99.0%); 1,067 of 1,079
(98.9%) in the EES group and 361 of 364 (99.2%) in the
SES group. At 1 year, the incidence of TLF was 3.75% for
EES and 3.05% for SES, which was not significantly
different (relative risk [RR]: 1.23 [95% CI: 0.64 to 2.37],
p  0.53). The rate of all death, cardiac death, and MI was
not statistically different between the 2 groups. The rate of
TLR was numerically lower in the SES group but was not
statistically significant (RR: 1.47 [95% CI: 0.61 to 3.53],
p  0.39]. As for definite and definite/probable stent
thrombosis, the rates numerically favored EES but also were
not statistically significant (definite/probable stent throm-
bosis 0.37% vs. 0.83% for EES vs. SES; RR: 0.45 [95% CI:
0.1 to 2.01], p  0.38). Most stent thrombosis events
occurred within 30 days of the index procedure and only 2
cases occurred after 30 days, 1 case in EES (0.1%) at 173
days resulting in TLR, and 1 case in SES (0.3%) at 273 days
resulting in MI (Fig. 2). When TLF rates were analyzed
separately between those who received routine angiographic
follow-up versus those who did not, there were no signifi-
Baseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
Characteristic Total (N  1,44
Age (yrs) 62.7 10.0
Male 931 (64.5)
Body mass index 25.0 3.1
Diabetes 550 (38.1)
Chronic renal failure 15 (1.0)
Hypertension 1,057 (73.3)
Dyslipidemia 1,093 (75.7)
Current smoker 384 (26.6)
Family history of CAD 127 (8.8)
Previous myocardial infarction 74 (5.1)
Previous PCI 129 (8.9)
Previous bypass surgery 18 (1.2)
Previous congestive heart failure 9 (0.6)
Cerebrovascular disease 95 (6.6)
Peripheral arterial disease 19 (1.3)
Multivessel disease 750 (52.0)
Left ventricular ejection fraction 61.3 9.5
Clinical indication
Silent ischemia 55 (3.8)
Chronic stable angina 644 (44.6)
Unstable angina 601 (41.6)
NSTEMI 98 (6.8)
STEMI 45 (3.1)
Medications at discharge
Aspirin 1,411 (99.2)
Clopidogrel 1,410 (99.2)
Statin 1,186 (83.4)
ACE inhibitor 467 (32.8)
Angiotensin-II receptor antagonist 475 (33.4)
Beta-blocker 872 (61.3)
Calcium-channel blocker 487 (34.2)
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; CAD  coronary artery disea
myocardial infarction; PCI  percutaneous coronary intervention; SES cant differences (Online Fig. 2).Subgroup analysis. Subgroup analysis regarding in-
segment and in-stent LL was performed according to the
presence of diabetes, long lesion, and multiple stenting. The
results in various subgroups were similar to those observed
in the entire population (i.e., SES showed statistically
insignificant but lower LL than EES) except in the diabetic
and multivessel stenting subgroups (Online Table 3 for
index lesions, Online Table 4 for all lesions, Online Table 5
for sensitivity analysis). In the diabetes subgroup, both the
in-stent and in-segment LL were significantly higher in the
EES group compared with the SES group (in-stent LL in
diabetes subgroup 0.23  0.36 mm vs. 0.10  0.27 mm; p
for superiority  0.0034). In the multivessel stenting
subgroup, the in-segment LL was significantly higher in the
EES group, but the difference in in-stent LL was not
statistically different (in-stent LL in the multivessel sub-
group 0.21  0.36 mm vs. 0.11  0.28 mm; p for
superiority  0.11). As for the clinical endpoint of TLF,
subgroup analysis was performed for diabetes, long lesion,
multivessel stenting, sex, acute MI, reference vessel diame-
EES (n  1,079) SES (n  364) p Value
62.5 10.1 63.4 9.9 0.12
703 (65.2) 228 (62.6) 0.39
25.0 3.1 25.0 2.9 0.89
402 (37.3) 148 (40.7) 0.25
12 (1.1) 3 (0.8) 0.77
791 (73.3) 266 (73.1) 0.93
823 (76.3) 270 (74.2) 0.42
278 (25.8) 106 (29.1) 0.21
99 (9.2) 28 (7.7) 0.39
56 (5.2) 18 (4.9) 0.85
99 (9.2) 30 (8.2) 0.59
12 (1.1) 6 (1.6) 0.42
8 (0.7) 1 (0.3) 0.46
58 (5.4) 37 (10.2) 0.01
13 (1.2) 6 (1.6) 0.59
564 (52.3) 186 (51.1) 0.70
61.4 9.4 60.8 9.8 0.33
0.12
39 (3.6) 16 (4.4)
472 (43.7) 172 (47.3)
464 (43.0) 137 (37.6)
76 (7.0) 22 (6.0)
28 (2.6) 17 (4.7)
1,061 (99.3) 350 (98.9) 0.48
1,058 (99.1) 352 (99.4) 0.74
888 (83.1) 298 (84.2) 0.65
352 (33) 115 (32.5) 0.87
355 (33.2) 120 (33.9) 0.82
660 (61.8) 212 (59.9) 0.52
360 (33.7) 127 (35.9) 0.46
 everolimus-eluting stent(s); NSTEMI  non–ST-segment elevation
s-eluting stent(s); STEMI  ST-segment elevation myocardial infarction.3)ter 2.75 mm, and estimated creatinine clearance of 60
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outcomes between EES and SES, and the results were
consistent across all subgroups, with no significant interac-
tion p values (Online Table 6, Fig. 3).
iscussion
n this randomized, prospective comparison of EES and
ES, the efficacy of EES in inhibiting neointimal growth
expressed as LL) was noninferior to the SES. Both stents
howed excellent LL profiles at 9-month angiographic
ollow-up. Clinical outcomes, including cardiac death, MI,
LR, and TLF, were mostly similar between the 2 stents,
lthough this study was underpowered to show differences
n clinical outcome between them. In addition, the definite
nd probable stent thrombosis rates were not statistically
ifferent between the 2 stents, although they were numer-
Baseline Lesion and Procedural CharacteristicsTable 2 Baseline Lesion and Procedural Cha
Parameter Total (N  1
Before index procedure
Location
Left anterior descending 956 (49
Left circumflex 421 (21
Right coronary 542 (28
Coronary graft 1 (0.
Multivessel disease 750 (52
ACC/AHA B2 or C type 991 (53
Total occlusion 66 (3.
Thrombus-containing 147 (7.
Bifurcation lesions 209 (10
Calcification 772 (41
Minimal luminal diameter 0.87 0
Reference vessel diameter 2.88 0
Diameter stenosis 69.68 1
Lesion length (mm) 20.35 1
Lesion length 20 mm 729 (40
After index procedure
No. of stents per lesion 1.21 0
No. of stents per patient 1.61 0
Total stent length per lesion (mm) 28.05 1
Total stent length per patient (mm) 37.54 2
Use of glycoprotein IIb/IIIa inhibitors 24 (1.
Final balloon pressure 14.32 3
Minimal luminal diameter (in-stent) 2.6 0
Minimal luminal diameter (in-segment) 2.22 0
Diameter stenosis (in-stent) 8.52 8
Diameter stenosis (in-segment) 18.85 1
Acute gain (in-stent) 1.73 0
Acute gain (in-segment) 1.35 0
Use of intravascular ultrasound 627 (43
Lesion success 1,905 (99
Device success 1,904 (99
Procedure success 1,891 (99
Values are n (%) or mean  SD. *All p values calculated using gener
calculated using †chi-square test or the ‡Student t test.
ACC/AHA  American College of Cardiology/American Heart Assoccally lower in the EES.There are some similarities and differences between the
EES and SES. Both everolimus and sirolimus are inhibitors
of the mammalian target of rapamycin, but everolimus is a
derivative of sirolimus, and the drug load in the EES is
smaller than in the SES (88 g vs. 150 g). In vitro
experiments reported greater efficacy of sirolimus in inhibi-
tion of smooth muscle cell proliferation (18). Furthermore,
the polymer technology and stent delivery systems differ,
which could result in differences in efficacy and clinical
outcomes between the 2 systems. Despite these differences,
it was shown in a porcine coronary model that SES and
EES are equally effective in the suppression of neointimal
formation (19).
In previous clinical trials, EES were superior to PES in
reduction of major clinical events after PCI. The relative
reductions in the incidence of the primary endpoints (TLF
ristics
EES (n  1,459) SES (n  468) p Value*
721 (49.6) 235 (50.4) 0.79
320 (22) 101 (21.7)
412 (28.3) 130 (27.9)
1 (0.1) 0 (0)
564 (52.3) 186 (51.1) 0.70†
746 (53) 245 (54.2) 0.62
48 (3.4) 18 (4) 0.58
114 (8.1) 33 (7.3) 0.57
155 (10.6) 54 (11.5) 0.54
589 (41.7) 183 (40.4) 0.64
0.87 0.48 0.88 0.5 0.68
2.87 0.49 2.88 0.52 0.65
69.69 15.29 69.64 15.39 0.94
20.31 12.05 20.48 11.51 0.80
546 (40.3) 183 (42.2) 0.53
1.21 0.47 1.19 0.42 0.26
1.64 0.97 1.53 0.86 0.04‡
27.91 13.46 28.51 13.16 0.43
37.79 25.09 36.77 24.68 0.50‡
19 (1.8) 5 (1.4) 0.62†
14.09 3.57 15.03 3.72 0.01
2.6 0.46 2.6 0.49 0.84
2.22 0.51 2.24 0.53 0.55
8.59 8.94 8.3 8.3 0.46
19.01 11.07 18.37 11.19 0.24
1.73 0.54 1.72 0.53 0.76
1.35 0.58 1.35 0.57 0.87
467 (43.3) 160 (44) 0.82†
1,445 (99.7) 460 (99.8) 0.82
1,447 (99.9) 457 (99.1) 0.10
1,434 (99.0) 457 (99.1) 0.93
stimating equations except for per-patient comparisons, which were
other abbreviations as in Table 1.racte
,927)
.8)
.9)
.2)
1)
)
.3)
5)
9)
.8)
.4)
.48
.5
5.31
1.92
.8)
.46
.95
3.38
4.98
7)
.63
.46
.51
.79
1.1
.54
.58
.5)
.7)
.7)
.0)
alized ein SPIRIT IV, major adverse cardiac events in the COMPARE
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However, EES have not been previously compared with
SES, which have been shown to have the lowest event rates.
Of all the commercially available DES, SES have been
shown to accumulate the least amount of LL and are the
most efficacious with regard to repeat revascularization
(6–10,20,21). Furthermore, SES outperformed PES in the
ZEST trial and zotarolimus-eluting stents in the SORT-
OUT III trial (11,12). Therefore, a head-to-head compar-
ison of EES and SES regarding efficacy and safety was
needed. In the present trial, the efficacy of EES was
noninferior to SES. The difference in mean LL was 0.04 
0.02 mm and 0.05  0.02 mm for in-stent and in-segment
analyses, respectively, which were well within the noninfe-
riority margin of 0.10 mm. The in-stent LL (0.19  0.35
mm) in the present study was in accord with previous trials
of EES, which showed LL of 0.11  0.27 mm in the
SPIRIT II trial at 6 months and 0.14  0.39 mm in the
SPIRIT III trial at 8 months after PCI (2,3). It should be
Quantitative Coronary Angiography Analysis (Per-Patient Analysis,Table 3 Quantitative Coronary Angiography Analysis (Per-Patie
Parameter Total (N  924)
Before procedure
Lesion length (mm) 21.27 12.36
Reference vessel diameter (mm) 2.88 0.49
Minimal luminal diameter (mm) 0.86 0.47
Diameter stenosis (%) 69.97 15.03
Immediately after procedure
Minimal luminal diameter (mm)
In-stent 2.62 0.45
In-segment 2.23 0.51
Diameter stenosis (%)
In-stent 8.39 8.77
In-segment 18.87 11.24
Acute gain (mm)
In-stent 1.76 0.54
In-segment 1.37 0.57
Follow-up at 9 months
Minimal luminal diameter (mm)
In-stent 2.44 0.54
In-segment 2.14 0.53
Diameter stenosis (%)
In-stent 14.35 13.18
In-segment 22.31 13.82
Late luminal loss (mm)
In-stent 0.18 0.35
In-segment 0.1 0.37
Binary restenosis (%)
In-stent 17 (1.8)
In-segment 30 (3.2)
Restenosis pattern (%)
Focal 28 (93.3)
Diffuse 1 (3.3)
Proliferative 0 (0.0)
Total occlusion 1 (3.3)
Values are expressed as mean  SD or n (%).
Abbreviations as in Table 1.noted that in the present study, the LL observed was lessthan what was expected at the onset of the trial, and
although the noninferiority was met, there was a consistent
trend in the superiority analysis toward lower LL (in-stent
and in-segment, all-lesion and index lesion) in the SES
group over the EES group. However, there were no differ-
ences in the rate of clinical events. The TLR rate, which is
the best clinical correlate of efficacy and LL, was 2.5% and
1.7% for EES and SES, respectively. These data are in line
with the recently presented but to-date-unpublished clinical
trials comparing EES versus SES, such as SORT-OUT IV
and ISAR-TEST-4 (Intracoronary Stenting and Angio-
graphic Results: Test Efficacy of 3 Limus-Eluting Stents
Trial), in which EES showed similar clinical efficacy com-
pared with SES up to 1 year (5,22,23). Event rates in this
study were extremely low for patients with such complexity
in both stents. In Asian subjects, the TLR rate for SES was
reported to be 5.7% at 1 year in an unrestricted population
of Japanese patients (24) and 1.4% in a selected group of
patients in a randomized Korean trial (11). Previous reports
Lesion)alysis, Index Lesion)
EES (n  708) SES (n  216) p Value
21.22 12.54 21.41 11.77 0.84
2.88 0.48 2.88 0.51 0.95
0.87 0.47 0.85 0.47 0.62
69.8 15.1 70.55 14.79 0.52
2.62 0.44 2.63 0.49 0.80
2.23 0.5 2.24 0.53 0.66
8.58 8.79 7.77 8.68 0.23
19.15 11.26 17.92 11.14 0.16
1.75 0.54 1.78 0.54 0.52
1.36 0.58 1.39 0.57 0.42
2.43 0.53 2.48 0.55 0.20
2.12 0.52 2.19 0.54 0.11
14.6 13.49 13.54 12.1 0.30
22.75 14.04 20.89 12.98 0.08
0.19 0.35 0.15 0.34 0.09
0.11 0.38 0.06 0.36 0.09
14 (2.0) 3 (1.4) 0.77
24 (3.4) 6 (2.8) 0.66
1.00
22 (91.7) 6 (100.0)
1 (4.2) 0 (0.0)
0 (0.0) 0 (0.0)
1 (4.2) 0 (0.0)Indexnt Anregarding the repeat revascularization rates of EES were
ite of c
get les
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respectively (4,5), which were very similar to our results.
In subgroup analysis, several subgroups showed signifi-
cant differences in in-stent LL; namely, the diabetic sub-
group and multivessel stenting subgroup. In these 2 sub-
groups, the difference in LL between EES and SES was
0.12 and 0.09 mm, respectively. The 1-sided upper 95% CI
was well above the noninferiority margin of 0.10 mm. This
could be due to a basic difference in the antiproliferative
efficacy of the 2 drugs. Although both stents showed
equivalent efficacy that probably will not significantly affect
efficacy outcome clinically, SES may be stronger in inhib-
iting neointimal formation after PCI due to the higher drug
Cumulative Incidence of Clinical Events Up to 1 Year (Intention-to-Table 4 Cumulative Incidence of Clinical Events Up to 1 Year (
30-Day Clinical Outcome Total (N  1,442) EES (n
Death
All 5 (0.35) 3
Cardiac 2 (0.14) 1
Noncardiac 3 (0.21) 2
Myocardial infarction
All 15 (1.04) 11
Periprocedural 11 (0.76) 9
Spontaneous 4 (0.28) 2
Target vessel 15 (1.04) 11
Nontarget vessel 0 (0) 0
Death or myocardial infarction 20 (1.39) 14
Ischemia-driven TLR 2 (0.14) 1
Ischemia-driven TVR 4 (0.28) 3
Stent thrombosis (ARC)
Definite 4 (0.28) 2
Probable 1 (0.07) 1
Definite or probable 5 (0.35) 3
Target lesion failure 17 (1.18) 12
Target vessel failure 19 (1.32) 14
1-Year Clinical Outcome Total (N  1,428) EES (n
Death
All 11 (0.77) 7
Cardiac 5 (0.35) 3
Noncardiac 6 (0.42) 4
Myocardial infarction
All 20 (1.4) 15
Periprocedural 13 (0.91) 11
Spontaneous 7 (0.49) 4
Target vessel 18 (1.26) 13
Nontarget vessel 2 (0.14) 2
Death or myocardial infarction 31 (2.17) 22
Ischemia-driven TLR 32 (2.24) 26
Ischemia-driven TVR 41 (2.87) 33
Stent thrombosis (ARC)
Definite 6 (0.42) 3
Probable 1 (0.07) 1
Definite or probable 7 (0.49) 4
Target lesion failure* 51 (3.57) 40
Target vessel failure 60 (4.2) 47
Values are n (%). *The main secondary clinical endpoint was target lesion failure, the compos
ARC  Academic Research Consortium; CI  confidence interval; RR  relative risk; TLR  tarload and greater smooth muscle cell–inhibiting efficacy. dThis could have resulted in the significant difference in LL
in subgroups that are prone to greater accumulation of
neointima. Second, there is intense controversy regarding
whether EES may be less efficacious in diabetic patients
compared with other DES. In both the SPIRIT IV and
COMPARE trials, in which EES were superior to the PES
in the entire population, the only subgroup in which this
was not seen was patients with diabetes (4,5). Third, there
is a possibility that our findings are the result of a play of
chance because the LL observed in patients with diabetes
receiving SES was extraordinarily low (lower than nondia-
betic subjects receiving SES). The LL did not differ
significantly between diabetic (0.23  0.36 mm) and non-
Per Patient)tion-to-Treat Per Patient)
79) SES (n  363) RR (95% CI) p Value
) 2 (0.55) 0.50 (0.08–3.01) 0.60
) 1 (0.28) 0.34 (0.02–5.36) 0.44
) 1 (0.28) 0.67 (0.06–7.40) 1.00
) 4 (1.1) 0.93 (0.3–2.89) 1.00
) 2 (0.55) 1.51 (0.33–6.97) 0.74
) 2 (0.55) 0.34 (0.05–2.38) 0.26
) 4 (1.1) 0.93 (0.30–2.89) 1.00
0 (0) — —
6 (1.65) 0.78 (0.30–2.03) 0.62
) 1 (0.28) 0.34 (0.02–5.36) 0.44
) 1 (0.28) 1.01 (0.11–9.67) 1.00
) 2 (0.55) 0.34 (0.05–2.38) 0.26
) 0 (0) — 1.00
) 2 (0.55) 0.50 (0.08–3.01) 0.60
) 5 (1.38) 0.81 (0.29–2.28) 0.78
5 (1.38) 0.94 (0.34–2.60) 1.00
67) SES (n  361)
) 4 (1.11) 0.59 (0.17–2.01) 0.48
) 2 (0.55) 0.51 (0.09–3.03) 0.61
) 2 (0.55) 0.68 (0.12–3.68) 0.65
) 5 (1.39) 1.01 (0.37–2.77) 0.98
) 2 (0.55) 1.86 (0.41–8.36) 0.54
) 3 (0.83) 0.45 (0.1–2.01) 0.38
) 5 (1.39) 0.88 (0.32–2.45) 0.79
) 0 (0) — 1.00
) 9 (2.49) 0.83 (0.38–1.78) 0.63
) 6 (1.66) 1.47 (0.61–3.53) 0.39
) 8 (2.22) 1.40 (0.65–2.99) 0.39
) 3 (0.83) 0.34 (0.07–1.67) 0.17
) 0 (0) — 1.00
) 3 (0.83) 0.45 (0.10–2.01) 0.38
) 11 (3.05) 1.23 (0.64–2.37) 0.53
13 (3.6) 1.22 (0.67–2.23) 0.51
ardiac death, target lesion-related myocardial infarction, and target lesion revascularization.
ion revascularization; TVR  target vessel revascularization; other abbreviations as in Table 1.TreatInten
 1,0
(0.28
(0.09
(0.19
(1.02
(0.83
(0.19
(1.02
(0)
(1.3)
(0.09
(0.28
(0.19
(0.09
(0.28
(1.11
(1.3)
 1,0
(0.66
(0.28
(0.37
(1.41
(1.03
(0.37
(1.22
(0.19
(2.06
(2.44
(3.09
(0.28
(0.09
(0.37
(3.75
(4.4)iabetic (0.17  0.34 mm) subjects in those receiving
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considerably and paradoxically lower in patients with dia-
betes (0.10  0.27 mm) than in the nondiabetic subjects
(0.18  0.38 mm).
The safety clinical endpoints in the trial were all similar
between EES and SES. However, there were similar trends
in the same direction for differences in components of
safety, including cardiac death, spontaneous MI, and stent
thrombosis, all of which numerically favored EES over SES.
Figure 2 Clinical Outcomes
Kaplan-Meier cumulative event curves up to 12 months are shown for (A) target le
(C) ischemia-driven target lesion revascularization (TLR), and (D) stent thrombosisAlthough this result in itself cannot be given any significantclinical relevance (because the study was underpowered to
show differences in safety), it needs to be interpreted in
context with the body of evidence that has been gathered for
EES. In 4 other relatively large-scale randomized, con-
trolled trials enrolling at least 1,000 patients (SPIRIT IV,
COMPARE, SORT-OUT IV, and ISAR-TEST), the
Academic Research Consortium definite and probable stent
thrombosis rates were 0.3%, 0.2%, 0.9%, and 1.4%, respec-
tively (4,5,22,23). Our results add to the existing evidence
ailure (TLF), (B) cardiac death and myocardial infarction (MI),sion f
.that EES have a very low rate of stent thrombosis at least up to 1
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be this low at longer term follow-up will need to be carefully
monitored because safety is an important issue.
Study limitations. First, although sufficiently powered to
show noninferiority of EES compared with SES in LL
using a very strict noninferiority margin, this study was
underpowered to detect any possible difference in clinical
endpoints because the primary endpoint was an angio-
graphic outcome. Therefore, any trend or numerical differ-
ence in clinical outcome needs to be taken as hypothesis
generating at best, and must be confirmed in larger ran-
domized trials or a careful meta-analysis of trials with
similar design. Second, the randomization of the stents was
3:1 rather than 1:1. This design was adapted to acquire as
much data as possible regarding the newly released EES.
The unbalanced randomization leads to sufficient number of
patients undergoing implantation with EES but a limited
number of patients receiving SES. This widens the possi-
bility that SES could unexpectedly perform better or worse
Figure 3 Subgroup Analysis
The rate of target lesion failure (TLF) was similar between everolimus-eluting stent
CCr  creatinine clearance; CI  confidence interval; MI  myocardial infarction;than its usual performance by chance, which could make anyinterpretation of the results very confusing. However, the
low rate of clinical events in the SES group is comparable to
another study enrolling similar complex, near real-world
type of patients (11). SES performed similar if not better
than any previous large-scale DES trial, and therefore, it is
highly unlikely that EES were noninferior to SES due to
unexpectedly poor outcomes in the SES group. Third, the
rate of angiographic follow-up was lower than expected.
However, because this study had another randomization
scheme (duration of dual antiplatelet therapy), we finally
enrolled 1,443 patients, which was much higher than the
1,223 patients necessary in the stent randomization scheme.
Conclusions
The EXCELLENT randomized prospective trial demon-
strated that EES were noninferior to SES in inhibition of
LL after stenting, which was corroborated by the similar
) and sirolimus-eluting stents (SES) across all subgroups.
relative risk.s (EES
RR rate of clinical outcomes.
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APPENDIX
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